All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

  TRANSLATE

The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

Phase III trial of pracinostat discontinued following results from interim analysis

By Sumayya Khan

Share:

Jul 7, 2020


On July 2, 2020, it was announced that the phase III, randomized study (NCT03151408) of pracinostat in combination with azacitidine in patients with AML who are unfit to receive standard intensive chemotherapy, due to age (≥ 75 years) or comorbidities, was discontinued following results from the interim analysis. The decision was made by the Independent Data Monitoring Committee and was based on a lack of efficacy in terms of overall survival (compared to azacitidine alone) and not on safety concerns.1,2

The study was a double-blind, placebo-controlled, multicenter trial, due to recruit 500 participants randomized into two treatment arms: (1) to receive pracinostat plus azacitidine or (2) to receive azacitidine plus placebo. Pracinostat was administered orally at 60 mg once daily, 3 times a week for 3 weeks, followed by 1 week of rest in each 28-day cycle. Azacitidine was administered subcutaneously or intravenously at 75 mg/m2 daily, for 7 days of each 28-day cycle. The primary outcome measure was efficacy, based on overall survival from randomization until death from any cause, assessed up to 60 months.2

Pracinostat is an oral histone deacetylase inhibitor that received orphan drug designation by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) based on the phase II study (NCT01912274). It is also being investigated in phase II studies in patients with high or very high-risk myelodysplastic syndromes. Pending further evaluation, patients currently enrolled in these studies will continue treatment.

References

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content